Nuclear Medicine and Molecular Imaging

Title Publication Date Language Citations
Production of 177Lu for Targeted Radionuclide Therapy: Available Options2015/02/17English179
Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?2017/09/19English150
In Vivo Cell Tracking with Bioluminescence Imaging2014/11/26English108
Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology2014/01/22English72
Radiomics in Oncological PET/CT: a Methodological Overview2019/01/15English69
Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases2017/03/16English68
Radiomics in Oncological PET/CT: Clinical Applications2017/10/20English67
Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept2018/01/11English58
Radiomics as a Quantitative Imaging Biomarker: Practical Considerations and the Current Standpoint in Neuro-oncologic Studies2018/02/01English54
Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma2015/04/08English48
Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging2012/11/03English48
Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer2013/09/06English47
Autoclustering of Non-small Cell Lung Carcinoma Subtypes on 18F-FDG PET Using Texture Analysis: A Preliminary Result2014/06/11English46
Deep Learning in Nuclear Medicine and Molecular Imaging: Current Perspectives and Future Directions2017/11/16English45
Current Consensus on I-131 MIBG Therapy2018/05/03English44
Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer2012/09/05English44
Potential Biomarker of L-type Amino Acid Transporter 1 in Breast Cancer Progression2010/11/24English44
68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer2017/03/07English43
Prognostic Significance of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Operable Primary Breast Cancer2012/08/25English41
68Ga-Labeled Radiopharmaceuticals for Positron Emission Tomography2010/10/12English41
Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges2016/08/06English40
Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer2011/04/20English39
New Frontiers in Molecular Imaging with Superparamagnetic Iron Oxide Nanoparticles (SPIONs): Efficacy, Toxicity, and Future Applications2020/02/08English39
The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma2016/08/06English39
Development of a 68Ga-Fluorinated Porphyrin Complex as a Possible PET Imaging Agent2011/12/16English39
The Prognostic Value of the Metabolic Tumor Volume in FIGO stage IA to IIB Cervical Cancer for Tumor Recurrence: Measured by F-18 FDG PET/CT2010/11/12English37
Salmonella-Mediated Cancer Therapy: Roles and Potential2016/06/01English37
Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives2018/03/28English36
Radiation Safety Issues in Y-90 Microsphere Selective Hepatic Radioembolization Therapy: Possible Radiation Exposure from the Patients2010/08/25English36
Prognostic Value of Metabolic Tumor Volume Estimated by 18 F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease2014/05/29English35